Article
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
The oncologist - 1 May 2015
Ali Siraj M, Sanford Eric M, Klempner Samuel J, Rubinson Douglas A, Wang Kai, Palma Norma A, Chmielecki Juliann, Yelensky Roman, Palmer Gary A, Morosini Deborah, Lipson Doron, Catenacci Daniel V, Braiteh Fadi, Erlich Rachel, Stephens Philip J, Ross Jeffrey S, Ou Sai-Hong Ignatius, Miller Vincent A
Abstract excerpt
BACKGROUND: Gastric cancer (GC) is a major global cancer burden and the second most common cause of global cancer-related deaths. The addition of anti-ERBB2 (HER2) targeted therapy to chemotherapy improves survival for ERBB2-amplified advanced GC patients; however, the majority of GC patients do not harbor this alteration and thus cannot benefit from targeted therapy under current practice paradigms. MATERIALS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.